Skip to main content
Jonathan Fish, MD, Pediatric Hematology & Oncology, New Hyde Park, NY, Long Island Jewish Medical Center

JonathanDFishMD

Pediatric Hematology & Oncology New Hyde Park, NY

Associate Professor of Pediatrics Zucker School of Medicine

Dr. Fish is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fish's full profile

Already have an account?

Education & Training

  • Children's Hospital of Philadelphia
    Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2004 - 2007
  • Zucker School of Medicine at Hofstra/Northwell at Cohen Children's Medical Center
    Zucker School of Medicine at Hofstra/Northwell at Cohen Children's Medical CenterResidency, Pediatrics, 2000 - 2003
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityClass of 2000
  • The University of Western Ontario
    The University of Western OntarioB.S., With distinction, 1996

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2003 - 2025
  • PA State Medical License
    PA State Medical License 2004 - 2008
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • President’s Award Nominee NSLIJ health system, 2013
  • Aflac ‘duck print’ Award Recipient 2013
  • Young Investigator Award American Society of Pediatric Hematology Oncology, 2008
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Arterial Stiffness in Childhood Cancer Survivors  
    Krystal JI, Reppucci M, Mayr T, Fish JD and Sethna C, Pediatr Blood Cancer, 1/1/2015
  • Fertility Preservation for Adolescent Women with Cancer  
    Fish JD, AMSTARs. Adolesc Med, 1/1/2012
  • reproducible method for non-invasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for pre-clinical modeling  
    Barrett DM, Seif AE, Carpentino C, Teachey DT, Fish JD, June CH, Grupp SA, and Reid GS, Blood, 1/1/2011
  • Join now to see all

Abstracts/Posters

  • PI-103, a dual inhibitor of mTOR and PI3kinase, potentiates rapamycin-mediated ALL cell death and inhibition of proliferation
    Fish JD, Sheen C, Hulitt J, Grupp SA and Brown VI, Pediatric Blood and Cancer; American Society of Pediatric Hematology Oncology Annual Meeting, 1/1/2008
  • Targeting of ALL by lentivirus engineered primary human T cells
    Fish JD, Milone M, Carpenito C, Lakhal M, Ofori E, Danet-Desnoyers G, Riley J, Grupp SA and June C, Pediatric Blood and Cancer; American Society of Pediatric Hematology Oncology Annual Meeting, 1/1/2007
  • PI3-Kinase inhibition induces ALL cell death, potentiates rapamycin, and prevents IL-7 mediated resistance to rapamycin
    Fish JD, Sheen C, Bruno M, Hulitt J, Grupp SA and Brown VI, Pediatric Blood and Cancer; American Society of Pediatric Hematology Oncology Annual Meeting, 1/1/2007
  • Join now to see all

Lectures

  • Arterial Stiffness in Childhood Cancer Survivors 
    1/1/2015
  • Costs of Screening of Childhood Cancer Survivors 
    1/1/2015
  • Adherence to Screening Recommendations Among Survivors of Childhood Cancer 
    1/1/2015
  • Join now to see all

Other

Press Mentions

  • New Data Notes Financial Considerations for How Health Systems Support Childhood Cancer Survivors
    New Data Notes Financial Considerations for How Health Systems Support Childhood Cancer SurvivorsJanuary 8th, 2020

Hospital Affiliations